News|Articles|May 22, 2026
The Shift Pharma Can’t Afford to Miss: From AI Experimentation to Execution
Author(s)EVERSANA
Trending on PharmExec
1
How MBA Graduates Can Break into Competitive Industries in 2026: 4 Practical Steps
2
FDA Approves Otsuka’s First-In-Class Simtriyo for Adults & Pediatric Patients
3
Pharma M&A Roundup: Oak Hill Bio Combines with RACC, Apnimed Plans $150 Million IPO, CORE Biomedicine Secures $21 Million Series A
4
Moving From Symptom Management to Disease Modification in Parkinson’s Research: Q&A with Dr. Jan Stoehr
5